Drugs · acquisition-cost intelligence
Zovirax
acyclovir· ingredient acyclovirAntivirals· ACYCLOVIR 50 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$10.45
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other acyclovir products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| Acyclovir suspension | $0.07005 | −$10.38 |
| acyclovir | $0.10072 | −$10.35 |
| acyclovir | $0.10206 | −$10.35 |
| Zovirax | $0.32429 | −$10.12 |
Medicare Part D coverage · CY2026
On 31 plan formularies · typical tier 2
Prior auth 7% · Step therapy 0% · Quantity limit 65% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.